Alpha-lipoic/JJ
acid/NN
is/VBZ
a/DT
potent/JJ
inhibitor/NN
of/IN
NF-kappa/NN
B/NN
activation/NN
in/IN
human/JJ
T/NN
cells/NNS
./.

Acquired/VBN
immunodeficiency/NN
syndrome/NN
(/(
AIDS/NN
)/)
results/VBZ
from/IN
infection/NN
with/IN
a/DT
human/JJ
immunodeficiency/NN
virus/NN
(/(
HIV/NN
)/)
./.
=====
The/DT
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
region/NN
of/IN
HIV/NN
proviral/JJ
DNA/NN
contains/VBZ
binding/VBG
sites/NNS
for/IN
nuclear/JJ
factor/NN
kappa/NN
B/NN
(/(
NF-kappa/NN
B/NN
)/)
,/,
and/CC
this/DT
transcriptional/JJ
activator/NN
appears/VBZ
to/TO
regulate/VB
HIV/NN
activation/NN
./.
=====
Recent/JJ
findings/NNS
suggest/VBP
an/DT
involvement/NN
of/IN
reactive/JJ
oxygen/NN
species/NNS
(/(
ROS/NN
)/)
in/IN
signal/NN
transduction/NN
pathways/NNS
leading/VBG
to/TO
NF-kappa/NN
B/NN
activation/NN
./.
=====
The/DT
present/JJ
study/NN
was/VBD
based/VBN
on/IN
reports/NNS
that/IN
antioxidants/NNS
which/WDT
eliminate/VBP
ROS/NN
should/MD
block/VB
the/DT
activation/NN
of/IN
NF-kappa/NN
B/NN
and/CC
subsequently/RB
HIV/NN
transcription/NN
,/,
and/CC
thus/RB
antioxidants/NNS
can/MD
be/VB
used/VBN
as/IN
therapeutic/JJ
agents/NNS
for/IN
AIDS/NN
./.
=====
Incubation/NN
of/IN
Jurkat/NN
T/NN
cells/NNS
(/(
1/CD
x/NN
10/CD
(/(
6/CD
)/)
cells/ml/NNS
)/)
with/IN
a/DT
natural/JJ
thiol/NN
antioxidant/NN
,/,
alpha-lipoic/JJ
acid/NN
,/,
prior/JJ
to/TO
the/DT
stimulation/NN
of/IN
cells/NNS
was/VBD
found/VBN
to/TO
inhibit/VB
NF-kappa/NN
B/NN
activation/NN
induced/VBN
by/IN
tumor/NN
necrosis/NN
factor-alpha/NN
(/(
25/CD
ng/ml/NN
)/)
or/CC
by/IN
phorbol/NN
12-myristate/NN
13-acetate/NN
(/(
50/CD
ng/ml/NN
)/)
./.
=====
The/DT
inhibitory/JJ
action/NN
of/IN
alpha-lipoic/JJ
acid/NN
was/VBD
found/VBN
to/TO
be/VB
very/RB
potent/JJ
as/IN
only/RB
4/CD
mM/NN
was/VBD
needed/VBN
for/IN
a/DT
complete/JJ
inhibition/NN
,/,
whereas/IN
20/CD
mM/NN
was/VBD
required/VBN
for/IN
N-acetylcysteine/NN
./.
=====
These/DT
results/NNS
indicate/VBP
that/IN
alpha-lipoic/JJ
acid/NN
may/MD
be/VB
effective/JJ
in/IN
AIDS/NN
therapeutics/NNS
./.